Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MEIP - MEI Pharma Inc


IEX Last Trade
3.1
-0.160   -5.161%

Share volume: 27,061
Last Updated: Fri 30 Aug 2024 09:59:45 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.26
-0.16
-4.91%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
34%
Profitability 43%
Dept financing 12%
Liquidity 75%
Performance 20%
Company vs Stock growth
vs
Performance
5 Days
-1.27%
1 Month
-9.36%
3 Months
6.90%
6 Months
-26.19%
1 Year
-8.28%
2 Year
-49.80%
Key data
Stock price
$3.10
P/E Ratio 
0.79
DAY RANGE
N/A - N/A
EPS 
$3.93
52 WEEK RANGE
$2.73 - $6.91
52 WEEK CHANGE
-$0.04
MARKET CAP 
20.655 M
YIELD 
N/A
SHARES OUTSTANDING 
6.663 M
DIVIDEND
$1.75
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
09/24/2024
BETA 
0.26
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$9,331
AVERAGE 30 VOLUME 
$15,450
Company detail
CEO: Daniel Gold
Region: US
Website: https://www.meipharma.com/
Employees: 127
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

mei pharma (nasdaq: meip) is a san diego-based oncology company focused on the clinical development of novel therapies for cancer. our lead drug candidate is pracinostat, a potential best-in-class, oral hdac inhibitor that has been granted breakthrough therapy designation from the fda in combination with azacitidine for the treatment of patients with newly diagnosed aml who are ≥75 years of age or unfit for intensive chemotherapy. our pipeline of drug candidates also includes me-401 (formerly pwt143), a next-generation oral pi3k delta inhibitor, and me-344, a novel mitochondrial inhibitor. for more, please go to www.meipharma.com.

Recent news